Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
114 Leser
Artikel bewerten:
(0)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of White River Capital, Inc. (RVR), BioMimetic Therapeutics Inc. (BMTI), Jeffries Group, Inc. (JEF) and Provectus Pharmaceuticals, Inc. (PVCT)

NEW YORK, Nov. 21, 2012 /PRNewswire/ --

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

White River Capital, Inc.
Levi & Korsinsky is investigating the Board of Directors of White River Capital, Inc. (NYSE MKT: RVR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company and its subsidiary, Coastal Credit, LLC, to an affiliate of Parthenon Capital Partners for $23 per share.

Click here to learn more about the investigation http://zlk.9nl.com/white-river-capital-rvr.

BioMimetic Therapeutics Inc.
Levi & Korsinsky is investigating the Board of Directors of BioMimetic Therapeutics Inc. (NasdaqGS: BMTI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Wright Medical Group Inc. (NasdaqGS: WMGI) under which shareholders BioMimetic shareholders will receive $1.50 in cash and 0.2482 shares of Wright common stock for each share of BioMimetic stock they own.

Click here to learn more about the investigation http://zlk.9nl.com/biomimetic-bmti.

Jeffries Group, Inc.
Levi & Korsinsky is investigating the Board of Directors of Jeffries Group, Inc. (NYSE: JEF) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to its largest shareholder, Leucadia National Corp. (NYSE: LUK) under which shareholders will receive 0.81 Leucadia shares for each share of Jefferies stock they own, representing an approximate value of $17.24 per share. At least one analyst set a price target of $19.00 per Jefferies share.

Click here to learn more about the investigation http://zlk.9nl.com/jefferies-group-jef, or call: 877-363-5972.

Provectus Pharmaceuticals, Inc.
Levi & Korsinsky, LLP is investigating Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), and its Board of Directors in connection with the compensation provided to certain of its executive officers.

To get more information, click here: http://zlk.9nl.com/provectus-pharmaceuticals-pvct, or call: 877-363-5972

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.